Compare Stocks: FDMT, CLDX, QURE, and BEAM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$24.12 +0.5%	$28.50	$20.23 ▼ $38.26	$2.49B	2.22	2.07 million shs	1.46 million shs
CLDX Celldex Therapeutics	$39.18 +6.2%	$39.16	$22.10 ▼ $45.14	$3.08B	0.84	937,056 shs	1.00 million shs
FDMT 4D Molecular Therapeutics	$13.76 +4.5%	$12.64	$6.47 ▼ $16.93	$760.10M	2.74	827,466 shs	971,551 shs
QURE uniQure	$44.93 +0.9%	$44.36	$8.73 ▼ $71.50	$3.12B	0.94	2.33 million shs	635,717 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	0.00%	-19.12%	-10.32%	-22.91%	+16.46%
CLDX Celldex Therapeutics	0.00%	-7.01%	-12.04%	+14.88%	+50.92%
FDMT 4D Molecular Therapeutics	0.00%	-12.02%	+8.04%	+42.84%	+93.39%
QURE uniQure	0.00%	+0.02%	-8.45%	+59.71%	+169.92%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$24.12 +0.5%	$28.50	$20.23 ▼ $38.26	$2.49B	2.22	2.07 million shs	1.46 million shs
CLDX Celldex Therapeutics	$39.18 +6.2%	$39.16	$22.10 ▼ $45.14	$3.08B	0.84	937,056 shs	1.00 million shs
FDMT 4D Molecular Therapeutics	$13.76 +4.5%	$12.64	$6.47 ▼ $16.93	$760.10M	2.74	827,466 shs	971,551 shs
QURE uniQure	$44.93 +0.9%	$44.36	$8.73 ▼ $71.50	$3.12B	0.94	2.33 million shs	635,717 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	0.00%	-19.12%	-10.32%	-22.91%	+16.46%
CLDX Celldex Therapeutics	0.00%	-7.01%	-12.04%	+14.88%	+50.92%
FDMT 4D Molecular Therapeutics	0.00%	-12.02%	+8.04%	+42.84%	+93.39%
QURE uniQure	0.00%	+0.02%	-8.45%	+59.71%	+169.92%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	2.69	Moderate Buy	$49.00	103.15% Upside
CLDX Celldex Therapeutics	2.85	Moderate Buy	$56.42	43.99% Upside
FDMT 4D Molecular Therapeutics	2.82	Moderate Buy	$28.56	107.53% Upside
QURE uniQure	2.76	Moderate Buy	$65.00	44.67% Upside

Current Analyst Ratings Breakdown

Latest FDMT, CLDX, QURE, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	FDMT 4D Molecular Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$20.00
9/10/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$46.00 ➝ $50.00
9/9/2026	BEAM Beam Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$65.00
9/2/2026	QURE uniQure	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold ➝ Outperform
8/25/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$80.00
8/17/2026	FDMT 4D Molecular Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$32.00
8/10/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/7/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$40.00 ➝ $46.00
8/7/2026	CLDX Celldex Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $53.00
7/31/2026	FDMT 4D Molecular Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$37.00

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$139.74M	17.83	N/A	N/A	$12.20 per share	1.98
CLDX Celldex Therapeutics	$1.54M	1,997.93	N/A	N/A	$7.93 per share	4.94
FDMT 4D Molecular Therapeutics	$85.21M	8.92	N/A	N/A	$8.85 per share	1.55
QURE uniQure	$16.10M	193.59	N/A	N/A	$3.19 per share	14.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$79.99M	-$0.86	N/A	N/A	N/A	-54.75%	-30.71%	-24.07%	11/3/2026 (Estimated)
CLDX Celldex Therapeutics	-$258.76M	-$4.35	N/A	N/A	N/A	N/A	-52.35%	-47.61%	11/9/2026 (Estimated)
FDMT 4D Molecular Therapeutics	-$140.11M	-$2.63	N/A	N/A	N/A	-194.74%	-41.33%	-35.90%	11/10/2026 (Estimated)
QURE uniQure	-$198.97M	-$4.01	N/A	N/A	N/A	-1,350.73%	-111.96%	-29.01%	11/9/2026 (Estimated)

Latest FDMT, CLDX, QURE, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	FDMT 4D Molecular Therapeutics	-$1.02	-$1.04	-$0.02	-$1.04	$3.62 million	$3.78 million
8/6/2026	Q2 2026	CLDX Celldex Therapeutics	-$1.06	-$0.94	+$0.12	-$0.94	$0.74 million	$0.02 million
8/4/2026	Q2 2026	BEAM Beam Therapeutics	-$1.11	-$1.18	-$0.07	-$1.18	$16.37 million	$0.49 million
7/29/2026	Q2 2026	QURE uniQure	-$0.8223	-$1.22	-$0.3977	-$1.22	$5.45 million	$5.84 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	0.09	14.57	14.57
CLDX Celldex Therapeutics	N/A	11.82	11.82
FDMT 4D Molecular Therapeutics	0.05	8.03	8.03
QURE uniQure	0.15	10.01	10.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
CLDX Celldex Therapeutics	N/A
FDMT 4D Molecular Therapeutics	99.27%
QURE uniQure	78.83%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.80%
CLDX Celldex Therapeutics	5.20%
FDMT 4D Molecular Therapeutics	7.90%
QURE uniQure	4.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	540	103.29 million	99.36 million	Optionable
CLDX Celldex Therapeutics	198	78.53 million	74.45 million	Optionable
FDMT 4D Molecular Therapeutics	196	55.24 million	50.88 million	Optionable
QURE uniQure	221	69.37 million	66.14 million	Optionable

FDMT, CLDX, QURE, and BEAM Headlines

Recent News About These Companies

FDA expands Bayer lung cancer drug approval

September 10, 2026 | statnews.comS

What to expect from UniQure’s upcoming Huntington’s gene therapy readout

September 10, 2026 | statnews.comS

Squarepoint Ops LLC Has $12.91 Million Stock Holdings in uniQure N.V. $QURE

September 10, 2026 | marketbeat.com

uniQure (QURE) Submitted AMT-130 for Accelerated Approval in Huntington’s Disease. Can Externally Controlled Data Support the Application?

September 8, 2026 | insidermonkey.com

uniQure N.V. $QURE Shares Sold by Readystate Asset Management LP

September 7, 2026 | marketbeat.com

QURE stock gains as uniQure moves closer to FDA review for Huntington’s gene therapy

September 6, 2026 | ad-hoc-news.deA

QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now

September 5, 2026 | investorplace.com

Wall Street Zen Downgrades uniQure (NASDAQ:QURE) to Sell

September 5, 2026 | americanbankingnews.com

uniQure (NASDAQ:QURE) Lowered to Sell Rating by Wall Street Zen

September 5, 2026 | marketbeat.com

uniQure submits ifezuntirgene inilparvovec BLA to US FDA to treat Huntington’s disease

September 4, 2026 | pharmabiz.comP

uniQure (NASDAQ:QURE) Shares Gap Up - Here's Why

September 4, 2026 | americanbankingnews.com

uniQure (NASDAQ:QURE) Coverage Initiated at William Blair

September 4, 2026 | americanbankingnews.com

uniQure files for US and UK approval for AMT-130 in Huntington’s disease

September 3, 2026 | thepharmaletter.comT

uniQure (NASDAQ:QURE) Trading Down 4.4% - Here's Why

September 3, 2026 | marketbeat.com

QURE Submits Application for Gene Therapy for Huntington's Disease

September 3, 2026 | zacks.com

QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now

September 3, 2026 | investorplace.com

UniQure, after setbacks, seeks FDA approval of Huntington’s gene therapy

September 2, 2026 | biopharmadive.comB

UniQure Submits Biologics License Application For AMT-130 In Huntington's Disease; Stock Up

September 2, 2026 | rttnews.com

Pharmalittle: We’re reading about a Huntington’s gene therapy, Novo’s challenges, and more

September 2, 2026 | statnews.comS

uniQure Submits BLA for AMT-130 in Huntington's Disease

September 2, 2026 | finance.yahoo.com

uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease

September 2, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FDMT, CLDX, QURE, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$24.12 +0.13 (+0.54%)

Closing price 04:00 PM Eastern

Extended Trading

$24.18 +0.05 (+0.23%)

As of 05:21 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Celldex Therapeutics NASDAQ:CLDX

$39.18 +2.28 (+6.18%)

Closing price 04:00 PM Eastern

Extended Trading

$39.18 0.00 (0.00%)

As of 04:40 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

4D Molecular Therapeutics NASDAQ:FDMT

$13.76 +0.59 (+4.48%)

Closing price 04:00 PM Eastern

Extended Trading

$13.75 -0.01 (-0.07%)

As of 04:54 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

uniQure NASDAQ:QURE

$44.93 +0.42 (+0.94%)

Closing price 04:00 PM Eastern

Extended Trading

$44.78 -0.15 (-0.32%)

As of 05:19 PM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FDMT, CLDX, QURE, and BEAM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FDMT, CLDX, QURE, and BEAM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FDMT, CLDX, QURE, and BEAM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FDMT, CLDX, QURE, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Celldex Therapeutics NASDAQ:CLDX

4D Molecular Therapeutics NASDAQ:FDMT

uniQure NASDAQ:QURE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FDMT, CLDX, QURE, and BEAM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FDMT, CLDX, QURE, and BEAM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FDMT, CLDX, QURE, and BEAM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FDMT, CLDX, QURE, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Celldex Therapeutics NASDAQ:CLDX

4D Molecular Therapeutics NASDAQ:FDMT

uniQure NASDAQ:QURE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools